Detection of Prostate Cancer Biomarker PCA3 with Electrochemical Apta-Sensor

Takita, Sarra; Nabok, Alexei; Lishchuk, Anna; Mussa, Magdi H.; Smith, David P.

doi:10.3390/iecb2022-12257

Cited by 5 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the modifications of the electrode’s surface did not reduce specificity in all the analyzed samples, showing a perfect correlation against the ELISA analyses, which indicates high versatility regarding the different kinds of samples. Further examples include the work of Takita and co-workers [ 34 ], who developed an aptasensor for PC diagnosis. This method was based on an electrochemical sensor combined with redox-labelled aptamers for PCA3 biomarker detection.…”

Section: Resultsmentioning

confidence: 99%

Microfluidic Platform Integrated with Carbon Nanofibers-Decorated Gold Nanoporous Sensing Device for Serum PSA Quantification

et al. 2023

View full text Add to dashboard Cite

Prostate cancer is a disease with a high incidence and mortality rate in men worldwide. Serum prostate-specific antigens (PSA) are the main circulating biomarker for this disease in clinical practices. In this work, we present a portable and reusable microfluidic device for PSA quantification. This device comprises a polymethyl methacrylate microfluidic platform coupled with electrochemical detection. The platinum working microelectrode was positioned in the outflow region of the microchannel and was modified with carbon nanofibers (CNF)-decorated gold nanoporous (GNP) structures by the dynamic hydrogen bubble template method, through the simultaneous electrodeposition of metal precursors in the presence of CNF. CNF/GNP structures exhibit attractive properties, such as a large surface to volume ratio, which increases the antibody’s immobilization capacity and the electroactive area. CNFs/GNP structures were characterized by scanning electron microscopy, energy dispersive spectrometry, and cyclic voltammetry. Anti-PSA antibodies and HRP were employed for the immune-electrochemical reaction. The detection limit for the device was 5 pg mL−1, with a linear range from 0.01 to 50 ng mL−1. The coefficients of variation within and between assays were lower than 4.40%, and 6.15%, respectively. Additionally, its clinical performance was tested in serum from 30 prostate cancer patients. This novel device was a sensitive, selective, portable, and reusable tool for the serological diagnosis and monitoring of prostate cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Microfluidic Platform Integrated with Carbon Nanofibers-Decorated Gold Nanoporous Sensing Device for Serum PSA Quantification

et al. 2023

View full text Add to dashboard Cite

show abstract

“…As shown in our earlier publication [39], the detection of PCA3 using cyclic voltammetry (CV) measurements on electrodes functionalised with a methylene-blue-labelled RNA aptamer demonstrated somewhat poor resolution. However, it contributed just to confirming the detection concept.…”

Section: Dpv Detection Of Pca3 In Buffermentioning

confidence: 96%

“…The aptamers were immobilised on the surface of gold screen-printed electrodes by the following procedure, shown schematically in Figure 1b. Before modification, gold electrodes were pretreated using the process detailed in our previous publications [26,37,39] with minor modifications. In this work, we used TCEP instead of 1,4-dithiothreitol (DTT) to break disulfide bonds in aptamers.…”

Section: Nucleic-acid-based Sensor Development 221 Fabrication Of The...mentioning

confidence: 99%

“…Despite increased interest in developing biosensor platforms that target PCA3, there have only been a few reports on electrochemical biosensors that detect PCA3 [34][35][36]. Our recent research combined the electrochemical methods with redox-labelled aptamers specific to PCA3 [37][38][39]. The detection principles of such aptasensors have been proven using different types of aptamers (RNA and DNA based) labelled with different redox tags (ferrocene and methylene blue) and different electrochemical techniques, namely, cyclic voltammograms (CV) [37][38][39], differential pulse voltammograms (DPV) [39], and electrochemical impedance spectroscopy (EIS) [37,38].…”

Section: Introductionmentioning

confidence: 99%

“…Our recent research combined the electrochemical methods with redox-labelled aptamers specific to PCA3 [37][38][39]. The detection principles of such aptasensors have been proven using different types of aptamers (RNA and DNA based) labelled with different redox tags (ferrocene and methylene blue) and different electrochemical techniques, namely, cyclic voltammograms (CV) [37][38][39], differential pulse voltammograms (DPV) [39], and electrochemical impedance spectroscopy (EIS) [37,38]. The resulting values of LDL in the picomolar range are similar or better as compared with those obtained in other research groups [34][35][36] and, therefore, very promising for the detection of traces of PCA3 in regular urine samples.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Enhanced Performance Electrochemical Biosensor for Detection of Prostate Cancer Biomarker PCA3 Using Specific Aptamer

Takita

Nabok

Lishchuk

et al. 2023

Eng

Self Cite

View full text Add to dashboard Cite

In the quest for the development of accurate, reliable, and cost-effective biosensing technology for early diagnostics of prostate cancer, we describe here an electrochemical biosensor combining a simple transducing method of differential pulse voltammetry (DPV) with an RNA-based aptamer labelled with a methylene blue redox group acting as a highly specific bioreceptor to the prostate cancer biomarker PCA3. A series of DPV measurements on screen-printed gold electrodes is functionalised with a redox-labelled aptamer in solutions (either buffer or synthetic urine) containing PCA3 in a wide range of concentrations from 0.1 picomolar (pM) to 10 nanomolar (nM). In these measurements, the current peak values correlate with the concentration of PCA3 and yield a low detection limit (LDL) of 0.1 pM. Furthermore, the binding kinetics study revealed the high affinity of the aptamer to the target PCA3 with the affinity constants KD of about 3.0 × 10−8 molar. In addition, the AFM study showed the increase in the molecular layer roughness caused by the binding of PCA3, which is a large RNA molecular fragment.

show abstract

Recent Electrochemical Advancements for Liquid-Biopsy Nucleic Acid Detection for Point-of-Care Prostate Cancer Diagnostics and Prognostics

Broomfield,

Kalofonou,

Bevan

et al. 2024

Biosensors

View full text Add to dashboard Cite

Current diagnostic and prognostic tests for prostate cancer require specialised laboratories and have low specificity for prostate cancer detection. As such, recent advancements in electrochemical devices for point of care (PoC) prostate cancer detection have seen significant interest. Liquid-biopsy detection of relevant circulating and exosomal nucleic acid markers presents the potential for minimally invasive testing. In combination, electrochemical devices and circulating DNA and RNA detection present an innovative approach for novel prostate cancer diagnostics, potentially directly within the clinic. Recent research in electrochemical impedance spectroscopy, voltammetry, chronoamperometry and potentiometric sensing using field-effect transistors will be discussed. Evaluation of the PoC relevance of these techniques and their fulfilment of the WHO’s REASSURED criteria for medical diagnostics is described. Further areas for exploration within electrochemical PoC testing and progression to clinical implementation for prostate cancer are assessed.

show abstract

Detection of Prostate Cancer Biomarker PCA3 with Electrochemical Apta-Sensor

Cited by 5 publications

References 27 publications

Microfluidic Platform Integrated with Carbon Nanofibers-Decorated Gold Nanoporous Sensing Device for Serum PSA Quantification

Microfluidic Platform Integrated with Carbon Nanofibers-Decorated Gold Nanoporous Sensing Device for Serum PSA Quantification

Enhanced Performance Electrochemical Biosensor for Detection of Prostate Cancer Biomarker PCA3 Using Specific Aptamer

Recent Electrochemical Advancements for Liquid-Biopsy Nucleic Acid Detection for Point-of-Care Prostate Cancer Diagnostics and Prognostics

Contact Info

Product

Resources

About